Quantitative phosphoproteomics reveals wee1 kinase as a therapeutic target in a model of proneural glioblastoma

Molecular Cancer Therapeutics

Volumn 15, Issue 6, 2016, Pages 1332-1343

  Lescarbeau, Rebecca S ^a   Lei, Liang ^b   Bakken, Katrina K ^c   Sims, Peter A ^d   Sarkaria, Jann N ^c   Canoll, Peter ^b   White, Forest M ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MAYO CLINIC   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; CYCLIN DEPENDENT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PHOSPHOTYROSINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; WEE 1 KINASE; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER; WEE1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DEATH; DNA DAMAGE; ENZYME PHOSPHORYLATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; QUANTITATIVE PHOSPHOPROTEOMIC; SIGNAL TRANSDUCTION; TRANSGENIC ORGANISM; TUMOR XENOGRAFT; ANIMAL; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MASS SPECTROMETRY; MICE; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTEOMICS; PYRAZOLES; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971539265     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0692-T     Document Type: Article

References (43)

1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology 2013;15:ii1-ii56.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710.
4. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, M. Mastrogianakis G, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455: 1061-8.
5. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
6. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
7. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344:1396-1401.
8. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 1995; 92:8493-7.
9. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
10. Goi K, Takagi M, Iwata S, Delia D, Asada M, Donghi R, et al. DNA damageassociated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res 1997;57:1895-902.
11. Lei L, Sonabend AM, Guarnieri P, Soderquist C, Ludwig T, Rosenfeld S, et al. Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS ONE 2011;6:30-2.
12. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, maintenance, and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protocols Pharmacol 2011;52:1-23.
13. Sarkaria JN, Carlson BL, Schroeder Ma, Grogan P, Brown PD, Giannini C, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-71.
14. Johnson H, White FM. Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. J Proteome Res 2014;13:4581-93.
15. Johnson H, Lescarbeau RS, Gutierrez JA, White FM. Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion. J Proteome Res 2013;12:1856-67.
16. Zhang Y, Wolf-Yadlin A, Ross PL, Pappin DJ, Rush J, Lauffenburger D a, et al. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 2005;4:1240-50.
17. Arneja A, Johnson H, Gabrovsek L, Lauffenburger DA, White FM. Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J Immunol 2013;192:123-35.
18. Curran TG, Bryson BD, Reigelhaupt M, Johnson H, White FM. Computer aided manual validation of mass spectrometry-based proteomic data. Methods 2013;61:219-26.
19. Pokorny JL, Calligaris D, Gupta SK, Iyekegbe DO, Mueller D, Bakken KK, et al. The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma. Clin Cancer Res 2015;21:1916-24.
20. Sonabend AM, Bansal M, Guarnieri P, Lei L, Amendolara B, Soderquist C, et al. The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression. Cancer Res 2014;74:1440-51.
21. Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, et al. MRIlocalized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A 2014;111:12550-12555.
22. Gonzalez C, Sims JS, Hornstein N, Mela A, Garcia F, Lei L, et al. Ribosome profiling reveals a cell-type specific translational landscape in glioma. J. Neuroscience 2014;34:10924-36.
23. Best DJ, Roberts DE. Algorithm AS 89: the upper Tail probabilities of Spearman's Rho. J Royal Stat Society 1975;24:377-9.
24. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via plateletderived growth factor receptors. Biochim Biophys Acta 1998;1378: F79-113.
25. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008;27:5527-41.
26. Boulton TG, Cobb MH. Identification of multiple extracellular signalregulated kinases (ERKs) with antipeptide antibodies. Cell Regul 1991; 2:357-71.
27. Wolf I, Rubinfeld H, Yoon S, Marmor G, Hanoch T, Seger R. Involvement of the activation loop of ERK in the detachment from cytosolic anchoring. J Biol Chem 2001;276:24490-7.
28. Himanen JP, Saha N, Nikolov DB. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 2007;19:534-42.
29. Perry JA, Kornbluth S. Cdc25 and Wee1: analogous opposites? Cell Div 2007;2:12.
30. Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2011;11:174-82.
31. Rogakou EP, Pilch DR, Orr a. H, Ivanova VS, Bonner WM. Double-stranded Brekas Induce Histone H2AX phosphorylation on Serine 139. J Biol Chem 1998;273:5858-68.
32. Kaufmann SH, Desnoyers S, Ottaviano Y, Apoptosis C, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of. Cancer Res 1993;53:3976-85.
33. Janicke RU. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-60.
34. Carlson BL, Grogan PT, Mladek AC, Schroeder M a., Kitange GJ, Decker PA, et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys 2009;75:212-9.
35. van Vuurden DG, Yazdani M, Bosma I, Broekhuizen a. JF, Postma TJ, Heimans JJ, et al. Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. PLoS ONE 2009;4: e5953.
36. Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean La, Hong RL, et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001;5:21-33.
37. Brenman JE, Christopherson KS, Craven SE, McGee AW, Bredt DS. Cloning and characterization of postsynaptic density 93, a nitric oxide synthase interacting protein. J Neurosci 1996;16:7407-15.
38. McGowan CH, Russell P. Cell-cycle regulation of human WEE1. EMBO J 1995;14:2166-75.
39. Rajeshkumar N V., De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011;17:2799-806.
40. Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012;2:524-39.
41. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22.
42. Sarcar B, Kahali S, Prabhu a. H, Shumway SD, Xu Y, Demuth T, et al. Targeting radiation-induced G2 checkpoint activation with the wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 2011;10:2405-14.
43. Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, Menck CFM, et al. Apoptosis in malignant glioma cells triggered by the temozolomideinduced DNA lesion O6-methylguanine. Oncogene 2007;26:186-97.